Studies & Results
TRIO021
A Randomized, multicenter, open-label, two-arm, Phase III neo-adjuvant study evaluating trastuzumab emtansine plus pertuzumab compared with chemotherapy plus trastuzumab emtansine and pertuzumab for patients with HER2-positive breast cancer
View FDA Study View EU Study
Presentations
ASCO 2016
Hurvitz SA, et al.
Pathologic complete reponses rates after neoadjuvant Trastuzumab emtansine (T-DM1) + pertuzumab vs docetaxel + carboplatin + Trastzumab + pertuzumab (TCH+P) treatment in patients with HER2-positive early breast cancer (KRISTINE/TRIO021)
SABCS 2016
de Haas SL, et al.
Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)
SABCS 2017
Prat A, et al.
Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer.
ASCO 2019
Hurvitz SA, et al.
Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.
SABCS 2020
Hurvitz SA, et al.
Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial
Publications
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org
Presentations
ASCO 2016
Hurvitz SA, et al.
Pathologic complete reponses rates after neoadjuvant Trastuzumab emtansine (T-DM1) + pertuzumab vs docetaxel + carboplatin + Trastzumab + pertuzumab (TCH+P) treatment in patients with HER2-positive early breast cancer (KRISTINE/TRIO021)
SABCS 2016
de Haas SL, et al.
Biomarker analysis from the neoadjuvant KRISTINE study in HER2-positive early breast cancer (EBC)
SABCS 2017
Prat A, et al.
Association of intrinsic subtypes with pathological complete response (pCR) in the KRISTINE neoadjuvant phase 3 clinical trial in HER2-positive early breast cancer.
ASCO 2019
Hurvitz SA, et al.
Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.
SABCS 2020
Hurvitz SA, et al.
Treatment-related amenorrhea with T-DM1 plus pertuzumab (KP) is lower than with docetaxel/carboplatin/trastuzumab/pertuzumab (TCHP) in the phase III neoadjuvant KRISTINE trial
Publications
For information on any of TRIO's clinical trials, please contact Valérie Bee, Director Project Management at valerie.bee@trioncology.org